Preclinical in vivo studies using actinium-225-labeled PSMA-targeting tracers (PSMA-617, RPS-074) so far showed impressive results such as complete tumor response of human PCa xenografts as well as prevention of metastasis formation resulting in significant increase in survival of the mice[9, 15]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.